Literature DB >> 16087397

Nucleotide analogs as novel anti-hepatitis B virus agents.

Radhakrishnan P Iyer1, Seetharamaiyer Padmanabhan, Guangrong Zhang, John D Morrey, Brent E Korba.   

Abstract

During the past decade, nucleotide analogs have emerged as novel antiviral agents against hepatitis B virus. Adefovir dipivoxil, a prototype phosphonate analog, has been approved for chronic hepatitis B virus therapy, and additional phosphonate analogs and di- and tri-nucleotides are under development. Several innovative prodrug derivatizations have also been reported to improve the oral bioavailability of nucleotide analogs, which usually carry a negative charge.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16087397     DOI： 10.1016/j.coph.2005.04.019

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN： 1471-4892            Impact factor:   5.547


  8 in total

1.  Orally bioavailable anti-HBV dinucleotide acyloxyalkyl prodrugs.

Authors:  John E Coughlin; Seetharamaiyer Padmanabhan; Guangrong Zhang; Cassandra J Kirk; Chandrika P Govardhan; Brent E Korba; Kathleen O'Loughlin; Carol E Green; Jon Mirsalis; John D Morrey; Radhakrishnan P Iyer
Journal:  Bioorg Med Chem Lett       Date:  2010-01-11       Impact factor: 2.823

2.  Synthesis and evaluation of the anti-hepatitis B virus activity of 4'-Azido-thymidine analogs and 4'-Azido-2'-deoxy-5-methylcytidine analogs: structural insights for the development of a novel anti-HBV agent.

Authors:  Kengo Onitsuka; Ryoh Tokuda; Nobuyo Kuwata-Higashi; Hiroki Kumamoto; Manabu Aoki; Masayuki Amano; Satoru Kohgo; Debananda Das; Kazuhiro Haraguchi; Hiroaki Mitsuya; Shuhei Imoto
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2019-09-12       Impact factor: 1.381

3.  SB 9200, a novel agonist of innate immunity, shows potent antiviral activity against resistant HCV variants.

Authors:  Meleri Jones; Morven E Cunningham; Peter Wing; Sampath DeSilva; Rupa Challa; Anjaneyulu Sheri; Seetharamaiyer Padmanabhan; Radhakrishnan P Iyer; Brent E Korba; Nezam Afdhal; Graham R Foster
Journal:  J Med Virol       Date:  2017-05-23       Impact factor: 2.327

4.  Metabolism, pharmacokinetics, tissue distribution, and stability studies of the prodrug analog of an anti-hepatitis B virus dinucleoside phosphorothioate.

Authors:  John E Coughlin; Rajendra K Pandey; Seetharamaiyer Padmanabhan; Kathleen G O'Loughlin; Judith Marquis; Carol E Green; Jon C Mirsalis; Radhakrishnan P Iyer
Journal:  Drug Metab Dispos       Date:  2012-02-10       Impact factor: 3.922

5.  Solid lipid nanoparticles loading adefovir dipivoxil for antiviral therapy.

Authors:  Xing-guo Zhang; Jing Miao; Min-wei Li; Sai-ping Jiang; Fu-qiang Hu; Yong-zhong Du
Journal:  J Zhejiang Univ Sci B       Date:  2008-06       Impact factor: 3.066

6.  Antiviral Efficacy and Host Innate Immunity Associated with SB 9200 Treatment in the Woodchuck Model of Chronic Hepatitis B.

Authors:  Kyle E Korolowicz; Radhakrishnan P Iyer; Stefanie Czerwinski; Manasa Suresh; Junming Yang; Seetharamaiyer Padmanabhan; Anjaneyulu Sheri; Rajendra K Pandey; Jeffrey Skell; Judith K Marquis; Bhaskar V Kallakury; Robin D Tucker; Stephan Menne
Journal:  PLoS One       Date:  2016-08-23       Impact factor: 3.240

7.  Antiviral Efficacy and Host Immune Response Induction during Sequential Treatment with SB 9200 Followed by Entecavir in Woodchucks.

Authors:  Manasa Suresh; Kyle E Korolowicz; Maria Balarezo; Radhakrishnan P Iyer; Seetharamaiyer Padmanabhan; Dillon Cleary; Rayomand Gimi; Anjaneyulu Sheri; Changsuek Yon; Bhaskar V Kallakury; Robin D Tucker; Nezam Afdhal; Stephan Menne
Journal:  PLoS One       Date:  2017-01-05       Impact factor: 3.240

Review 8.  Recent Drug Development in the Woodchuck Model of Chronic Hepatitis B.

Authors:  Manasa Suresh; Stephan Menne
Journal:  Viruses       Date:  2022-08-03       Impact factor: 5.818
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.